Dr. Peter Carmeliet joins the State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun-Yat-Sen University as a Guest Professor
Source: Zhongshan Ophthalmic Center of Sun Yat-sen University
Edited by: Liu Nian
Recently, Dr. Peter Carmeliet, an internationally eminent Belgian biomedical scientist, joins the State Key Laboratory of Ophthalmology (SKLO), Zhongshan Center (ZOC), Sun-Yat-Sen University (SYSU) in Guangzhou as a Guest Professor. SKLO is the only one of its kind in China and is supported by the central Chinese government. ZOC is the all-time number one eye hospital in China. SKLO and ZOC constitute the largest eye care and research center in the world. SYSU is the 2nd top-ranked university in China in terms of numbers of top 1% research disciplines in the world; the 2nd in terms of campus area; and the 5th in general ranking.
Dr. Myriam Baes, Dr. Peter Carmeliet, Dr. Yizhi Liu, Dr. Luc Schoonjans, Dr. Xuri Li, Dr. Weisi Lu
（From left to right）
Dr. Carmeliet is an elected member of the German Academy Sciences Leopoldina, Dutch Royal Academy of Sciences, EU Academy of Sciences, and European Molecular Biology Organization (EMBO). Dr. Carmeliet is heading a world-leading research team with interests in vascular metabolism, (ocular and tumor) angiogenesis, regenerative (vascular) medicine, ocular diseases, and bioinformatic multi-omic analysis of endothelial cells in health and disease. Dr. Carmeliet has made numerous milestone contributions to the fields.
Dr. Carmeliet is also a Professor at VIB-University of Leuven, Belgium. The University of Leuven (KU Leuven) has ranked number one for many years in Europe in terms of innovation. KU Leuven was founded in 1425 and is one of the oldest and most prestigious universities in the world.
Dr. Carmeliet has published more than 646 publications (94 IF>20, 243 IF>10, h-index 126) till March 2018, and is ranked by Science Match as top eight most cited authors in General Biomedicine. Dr. Carmeliet is on the editorial board of Cancer Cell, was a consulting editor for Science, and has more than 72 patents. Based on Dr. Carmeliet’s research, several biocompanies have been founded and clinical trials have been launched.
Dr. Carmeliet expressed that with the great enthusiasm for science, ample funding, and the growing young talents at SKLO/ZOC, he is most confident about a productive, long-term and successful joint venture in both basic and translational research. SKLO/ZOC, as a leading research center in China, embraces Dr. Peter Carmeliet with tremendous warmth and concrete support. SKLO/ZOC is excited and looking forward to working with Dr. Peter Carmeliet towards the most forefront sciences in the fields of vascular, stem cell, ocular and cancer biology as well as regenerative medicine for the years to come. With Dr. Carmeliet’s immense knowledge and experience in multiple fields of biomedical research, it is anticipated that research at SKLO/ZOC will soon take off to a further higher level with a tangible ambition of building a world-leading international innovation center of ophthalmology research.
Dr. Carmeliet’s arrival signifies the beginning of a new era of SKLO/ZOC in terms of its worldwide influence, internationalization, and scientific development.